Gilead

Causaly Raises $60 Million in Series B Funding to Catalyze AI-powered Preclinical Discovery

Retrieved on: 
Thursday, July 13, 2023
Research, Technology, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Other Science, Wolt, National Institute of Environmental Health Sciences, IPO, ICONIQ, Education, Regeneron Pharmaceuticals, Red Ventures, Lung cancer, Uber, Biomedical Research, Brazing, Multiple sclerosis, Gilead, EBRD, Organization, Criticism of the Food and Drug Administration, Investment, Snowflake, Novo Nordisk, Growth, Adyen, Drug discovery, Zoom, Johnson & Johnson, Ecosystem, AI, BambooHR, Ali Baba, Food, Pharmaceutical industry, Medical device, Airbnb, Datadog, Chime, Index Ventures, DocuSign, Atlantic Ocean, Procore

Causaly , the leading AI platform for biomedical research, closed $60m in Series B funding led by ICONIQ Growth , with participation from Index Ventures , Marathon Venture Capital , EBRD , Pentech Ventures and Visionaries Club .

Key Points: 
  • Causaly , the leading AI platform for biomedical research, closed $60m in Series B funding led by ICONIQ Growth , with participation from Index Ventures , Marathon Venture Capital , EBRD , Pentech Ventures and Visionaries Club .
  • The latest round comes after the company recently tripled revenue and customers, now serving 12 of the top 20 pharma companies.
  • Developing a new drug is an arduous process that typically spans over a decade, involving extensive research, development and rigorous clinical trials.
  • Causaly’s AI solution is specifically designed to untangle this complexity, empowering scientists to deeply understand the underlying disease biology.

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Retrieved on: 
Monday, July 10, 2023
Duke University, Intellectual property, Central nervous system, CLO, General counsel, Biotechnology, Human, DSM-IV codes, Gilead, Boston University School of Law, Genzyme, Knee pain, Millennium, Corporation, Therapy, Neurology, Pharmaceutical industry, Voyager, Fourth, fifth, and sixth derivatives of position

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (CLO).

Key Points: 
  • CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (CLO).
  • Fahey Sandell brings more than 25 years of legal experience spanning in-house roles at multiple biotechnology and pharmaceutical companies.
  • She most recently served as CLO, Corporate Secretary, and Compliance Officer of Jounce Therapeutics, Inc.
    “Jacqui’s breadth of expertise across securities, business development, regulatory, intellectual property, and multiple other legal disciplines makes her a strong addition to the growing Voyager team,” said Al Sandrock, M.D., Ph.D., Chief Executive Officer of Voyager.
  • Fahey Sandell previously held senior positions at Millennium: The Takeda Oncology Company and Genzyme Corporation, and she has worked at multiple top-tier law firms.

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Retrieved on: 
Monday, July 3, 2023
CD19, Takeda, Osteoporosis, CD20, Neoplasm, Biogen, VEGF, Patient, Epitope, Epithelial cell adhesion molecule, Zymeworks, Therapy, Lonza, Bone marrow, Research, Genentech, Gilead, EMA, Boehringer Ingelheim, ABL, Growth, ADC, PD-1, FDA, III, NMPA, Hubert Mordek, Roche, Docetaxel, Bispecific monoclonal antibody, Gilead Sciences, CD3, IGM, HER2, Immunoglobulin M, Conjugation, Cancer, Macrogen, Dragonfly, NSCLC, Antibody, Immunotherapy, Acute myeloid leukemia, CD33, Syndrome, Immune system, Pembrolizumab, Economics, Caris, Jazz, PRV, CEA, Diffuse large B-cell lymphoma, NHL, LAS, MDS, AML, CD123, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, BCMA, Vaccine, Fine chemical, Pharmaceutical industry, WNT

LAS VEGAS, July 3, 2023 /PRNewswire/ -- DelveInsight's 'Bispecific Antibody Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the bispecific antibody competitive domain.

Key Points: 
  • The bispecific antibody pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
  • Over 250+ bispecific antibody companies are evaluating 300+ bispecific antibody drugs in various stages of development, and their anticipated acceptance in the bispecific antibody market would significantly increase market revenue.
  • Promising bispecific antibody pipeline drugs such as Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and others are under different phases of bispecific antibody clinical trials.
  • The collaboration is intended to help in the development and manufacturing of ABL Bio's new bispecific antibody product.

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Retrieved on: 
Monday, July 3, 2023
CD19, Takeda, Osteoporosis, CD20, Neoplasm, Biogen, VEGF, Patient, Epitope, Epithelial cell adhesion molecule, Zymeworks, Therapy, Lonza, Bone marrow, Research, Genentech, Gilead, EMA, Boehringer Ingelheim, ABL, Growth, ADC, PD-1, FDA, III, NMPA, Hubert Mordek, Roche, Docetaxel, Bispecific monoclonal antibody, Gilead Sciences, CD3, IGM, HER2, Immunoglobulin M, Conjugation, Cancer, Macrogen, Dragonfly, NSCLC, Antibody, Immunotherapy, Acute myeloid leukemia, CD33, Syndrome, Immune system, Pembrolizumab, Economics, Caris, Jazz, PRV, CEA, Diffuse large B-cell lymphoma, NHL, LAS, MDS, AML, CD123, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, BCMA, Vaccine, Fine chemical, Pharmaceutical industry, WNT

LAS VEGAS, July 3, 2023 /PRNewswire/ -- DelveInsight's 'Bispecific Antibody Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the bispecific antibody competitive domain.

Key Points: 
  • The bispecific antibody pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
  • Over 250+ bispecific antibody companies are evaluating 300+ bispecific antibody drugs in various stages of development, and their anticipated acceptance in the bispecific antibody market would significantly increase market revenue.
  • Promising bispecific antibody pipeline drugs such as Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and others are under different phases of bispecific antibody clinical trials.
  • The collaboration is intended to help in the development and manufacturing of ABL Bio's new bispecific antibody product.

AHF: Advocates Slam Gilead over Drug Profiteering

Retrieved on: 
Wednesday, June 21, 2023
AIDS, Health, Consumer, Healthcare Reform, Public Policy, Government, Pharmaceutical, Advocacy Group Opinion, Philanthropy, Infectious Diseases, LGBTQ+, Communications, Foundation, Health Insurance, Social Activism, Gilead, AHF, San Francisco Bay Area, Gilead Sciences, HIV, AIDS Healthcare Foundation, Pharmacy, World (magazine), Pharmaceutical industry

On Wednesday, June 21st, advocates and mobilizers affiliated with AIDS Healthcare Foundation (AHF) will host a protest targeting HIV and Hepatitis C drug giant Gilead Sciences over the Bay Area company’s drug pricing and policies.

Key Points: 
  • On Wednesday, June 21st, advocates and mobilizers affiliated with AIDS Healthcare Foundation (AHF) will host a protest targeting HIV and Hepatitis C drug giant Gilead Sciences over the Bay Area company’s drug pricing and policies.
  • The action is part of a yearlong aggressive advocacy campaign by AHF hammering Gilead and Daniel O’Day, its multimillionaire CEO, over his and the company’s drug profiteering.
  • Advocates are protesting Gilead’s tone-deaf greed, particularly illegal restrictions the company placed early last year on access to 340B drug pricing for its branded hepatitis C treatments for certain pharmacies.
  • Gilead now is one of more than 15 major drug companies that illegally have placed such restrictions on drugs.

AHF Advocates to Keep Hammering Gilead CEO over Drug Profiteering

Retrieved on: 
Friday, June 16, 2023
Women, Infectious Diseases, LGBTQ+, Men, Public Policy, Government, Healthcare Reform, General Health, Pharmaceutical, Consumer, Health, AHF, San Francisco Bay Area, Gilead Sciences, HIV, Pharmacy, World (magazine), Multimedia, Gilead, AIDS, AIDS Healthcare Foundation, Pharmaceutical industry

On Friday, June 16th, advocates and mobilizers affiliated with AIDS Healthcare Foundation (AHF) will host a protest targeting HIV and Hepatitis C drug giant Gilead Sciences over the Bay Area company’s drug pricing and policies.

Key Points: 
  • On Friday, June 16th, advocates and mobilizers affiliated with AIDS Healthcare Foundation (AHF) will host a protest targeting HIV and Hepatitis C drug giant Gilead Sciences over the Bay Area company’s drug pricing and policies.
  • The action is part of a yearlong aggressive advocacy campaign by AHF hammering Gilead and Daniel O’Day, its multimillionaire CEO, over his and the company’s drug profiteering.
  • View the full release here: https://www.businesswire.com/news/home/20230614213003/en/
    Advocates and mobilizers affiliated with AIDS Healthcare Foundation (AHF) will host a protest targeting HIV and Hepatitis C drug giant Gilead Sciences and its CEO Daniel O'Day over the Bay Area company’s drug pricing and policies.
  • Gilead now is one of more than 15 major drug companies that illegally have placed such restrictions on drugs.

New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

Retrieved on: 
Thursday, June 8, 2023
PDAC, TNBC, Communication, Chronic lymphocytic leukemia, Precigen, Doctor of Philosophy, Investigational New Drug, GILD, MD, Patient, NYSE, News, Bone marrow, CLL, University, Oncolytics Biotech, Acute lymphoblastic leukemia, DLBCL, NK, Research, MD Anderson Cancer Center, B-cell lymphoma, Gilead, GSK plc, ONC, TSX, PD-1, FDA, Pancreatic cancer, GSK, Gilead Sciences, Trinket, Pela, ALL, Cancer, ACT Biotech Inc, National Cancer Institute, Standard of care, Therapy, ORR, Inflammation, Pelareorep, Triple-negative breast cancer, Cell death, Paclitaxel, Dostarlimab, Mantle cell lymphoma, MCL, FTD, Breast cancer, Pharmaceutical industry, Medical imaging, Cryptocurrency, EU, Dragonfly, Agency

VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer. A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies. How we arm ourselves in the battle against cancer is rapidly changing, thanks to novel mechanisms giving important results, such as those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Gilead Sciences, Inc. (NASDAQ: GILD), iTeos Therapeutics, Inc. (NASDAQ: ITOS), GSK plc (NYSE: GSK), and Precigen, Inc. (NASDAQ: PGEN).

Key Points: 
  • VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer.
  • A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies.
  • At this year's Future of Oncology Virtual Symposium in early April, Oncolytics was selected to participate in a panel presentation called Novel Mechanisms with Important Readouts.
  • Pelareorep's impacts on cancer are also being researched, including through Oncolytics' first and longest-standing focus on its HR-positive HER2-negative metastatic breast cancer program.

New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

Retrieved on: 
Thursday, June 8, 2023
PDAC, TNBC, Communication, Chronic lymphocytic leukemia, Precigen, Doctor of Philosophy, Investigational New Drug, GILD, MD, Patient, NYSE, News, Bone marrow, CLL, University, Oncolytics Biotech, Acute lymphoblastic leukemia, DLBCL, NK, Research, MD Anderson Cancer Center, B-cell lymphoma, Gilead, GSK plc, ONC, TSX, PD-1, FDA, Pancreatic cancer, GSK, Gilead Sciences, Trinket, Pela, ALL, Cancer, ACT Biotech Inc, National Cancer Institute, Standard of care, Therapy, ORR, Inflammation, Pelareorep, Triple-negative breast cancer, Cell death, Paclitaxel, Dostarlimab, Mantle cell lymphoma, MCL, FTD, Breast cancer, Pharmaceutical industry, Medical imaging, Cryptocurrency, EU, Dragonfly, Agency

VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer. A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies. How we arm ourselves in the battle against cancer is rapidly changing, thanks to novel mechanisms giving important results, such as those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Gilead Sciences, Inc. (NASDAQ: GILD), iTeos Therapeutics, Inc. (NASDAQ: ITOS), GSK plc (NYSE: GSK), and Precigen, Inc. (NASDAQ: PGEN).

Key Points: 
  • VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer.
  • A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies.
  • At this year's Future of Oncology Virtual Symposium in early April, Oncolytics was selected to participate in a panel presentation called Novel Mechanisms with Important Readouts.
  • Pelareorep's impacts on cancer are also being researched, including through Oncolytics' first and longest-standing focus on its HR-positive HER2-negative metastatic breast cancer program.

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

Retrieved on: 
Friday, May 26, 2023
Optimism, Senior, Survival, Merck Group, Doctor of Philosophy, IMGN, GILD, MD, NUALS Arts and Literary Annual Meet, Patient, Sacituzumab govitecan, SVP, News, Business development, Brain, DPD, Hope, Mirvetuximab soravtansine, B-cell lymphoma, Gilead, Bortezomib, ONC, Randomness, TSX, Entrepreneurship, Safety, Axicabtagene ciloleucel, Gilead Sciences, Oncolytics Biotech, Neuro-Oncology (journal), CDK, Overalls, Cancer, Lung cancer, ImmunoGen, CBR, National Cancer Institute, Lymphoma, Daratumumab, ORR, Glioma, Pfizer, Progression-free survival, Paclitaxel, PVD, Dexamethasone, Fast track (FDA), ASCO, American Society of Clinical Oncology, Mantle cell lymphoma, Pelareorep, EHA, Multiple myeloma, Metastatic breast cancer, Society, Female, Breast cancer, Pharmaceutical industry, Birth control, Vaccine

VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group  -  The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there's plenty of optimism ahead for the findings and intriguing data set to be presented, with oral presentations from some of the biotech sector's finest and up-and-comers, including from Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoGen, Inc. (NASDAQ:IMGN), Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Legend Biotech Corporation (NASDAQ:LEGN), and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

Key Points: 
  • According to the National Cancer Institute, HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases.
  • It's worth noting that Oncolytics has stated that it will also be presenting updated data from May 2023 at the oral presentation.
  • Additional data will be presented during the 2023 ASCO oral presentation.
  • Bringing in eight presentations to ASCO and EHA 2023 Annual Meetings, Legend Biotech Corporation (NASDAQ:LEGN) is set to deliver new and updated data from the CARTITUDE Clinical Development Program.

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

Retrieved on: 
Friday, May 26, 2023
Optimism, Senior, Survival, Merck Group, Doctor of Philosophy, IMGN, GILD, MD, NUALS Arts and Literary Annual Meet, Patient, Sacituzumab govitecan, SVP, News, Business development, Brain, DPD, Hope, Mirvetuximab soravtansine, B-cell lymphoma, Gilead, Bortezomib, ONC, Randomness, TSX, Entrepreneurship, Safety, Axicabtagene ciloleucel, Gilead Sciences, Oncolytics Biotech, Neuro-Oncology (journal), CDK, Overalls, Cancer, Lung cancer, ImmunoGen, CBR, National Cancer Institute, Lymphoma, Daratumumab, ORR, Glioma, Pfizer, Progression-free survival, Paclitaxel, PVD, Dexamethasone, Fast track (FDA), ASCO, American Society of Clinical Oncology, Mantle cell lymphoma, Pelareorep, EHA, Multiple myeloma, Metastatic breast cancer, Society, Female, Breast cancer, Pharmaceutical industry, Birth control, Vaccine

VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group  -  The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there's plenty of optimism ahead for the findings and intriguing data set to be presented, with oral presentations from some of the biotech sector's finest and up-and-comers, including from Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoGen, Inc. (NASDAQ:IMGN), Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Legend Biotech Corporation (NASDAQ:LEGN), and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

Key Points: 
  • According to the National Cancer Institute, HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases.
  • It's worth noting that Oncolytics has stated that it will also be presenting updated data from May 2023 at the oral presentation.
  • Additional data will be presented during the 2023 ASCO oral presentation.
  • Bringing in eight presentations to ASCO and EHA 2023 Annual Meetings, Legend Biotech Corporation (NASDAQ:LEGN) is set to deliver new and updated data from the CARTITUDE Clinical Development Program.